Document Detail


Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease.
MedLine Citation:
PMID:  24583879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The interstitial lung diseases (ILD) include a large number of chronic, progressive, irreversible respiratory disorders involving pulmonary fibrosis, the most common of which are idiopathic pulmonary fibrosis and scleroderma lung disease (SSc ILD). Because bleomycin causes lung fibrosis when used in cancer chemotherapy, it is used to model human ILD in rodents. In most studies, bleomycin has been delivered directly into the lung by intratracheal or intraoral administration. Here we have compared the effects in mice of bleomycin delivered directly into the lungs (direct model) or systemically using osmotic minipumps (pump model) to determine which more closely resembles human ILD. The pump model is more similar to human SSc ILD in that: 1) lung injury/fibrosis is limited to the subpleural portion of the lung in the pump model and in SSc ILD, whereas the entire lung is affected in the direct model; 2) conversely, there is massive inflammation throughout the lung in the direct model, whereas inflammation is limited in the pump model and in SSc ILD; 3) hypertrophic type II alveolar epithelial cells are present at high levels in SSc ILD and in the pump model but not in the direct model; and 4) lung fibrosis is accompanied by dermal fibrosis. The pump model is also move convenient and humane than the direct model because there is less weight loss and mortality.
Authors:
Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman
Related Documents :
15808889 - Assessing the predictive value of means-end-chain theory: an application to meat produc...
9565189 - A critical review of the biopsychosocial model.
18400549 - Validity of the local nonlinear arterial flow theory: influence of the upstream and dow...
11722829 - Theoretical applications of smoking cessation interventions to individuals with medical...
20161289 - Central limit theorems and uniform laws of large numbers for arrays of random fields.
12639269 - Psychoanalytic interpretations: word-music and translation.
23557129 - A predictive microarray-based biomarker for early detection of alzheimer's disease inte...
12194349 - The evaluation and use of a portable tepc system for measuring in-flight exposure to co...
20968549 - Development and use of an acoustic device to estimate size distribution of catfish in c...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2014-02-28
Journal Detail:
Title:  American journal of physiology. Lung cellular and molecular physiology     Volume:  306     ISSN:  1522-1504     ISO Abbreviation:  Am. J. Physiol. Lung Cell Mol. Physiol.     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-04-16     Completed Date:  2014-06-05     Revised Date:  2014-06-06    
Medline Journal Info:
Nlm Unique ID:  100901229     Medline TA:  Am J Physiol Lung Cell Mol Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  L736-48     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibiotics, Antineoplastic / administration & dosage*
Bleomycin / administration & dosage*
Caveolin 1 / metabolism
Drug Delivery Systems*
Extracellular Matrix Proteins / metabolism
Fluorescent Antibody Technique
Humans
Immunoenzyme Techniques
Infusion Pumps*
Lung Diseases, Interstitial / drug therapy*,  metabolism,  pathology
Male
Mice
Mice, Inbred C57BL
Osmosis
Pulmonary Alveoli / drug effects,  pathology
Scleroderma, Systemic / drug therapy*,  metabolism,  pathology
Weight Loss / drug effects
Grant Support
ID/Acronym/Agency:
K01-AR-054143/AR/NIAMS NIH HHS; P20-RR-016434/RR/NCRR NIH HHS; P20-RR-016434-09S/RR/NCRR NIH HHS; P20-RR-02194/RR/NCRR NIH HHS; R01 AR062078/AR/NIAMS NIH HHS; R01-AR-062078/AR/NIAMS NIH HHS; R03-AR-056767/AR/NIAMS NIH HHS; R21-AT-004450/AT/NCCAM NIH HHS; T32 AR050958/AR/NIAMS NIH HHS; T32-AR-05095/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Caveolin 1; 0/Extracellular Matrix Proteins; 11056-06-7/Bleomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  c-Kit immunoexpression delineates a putative endothelial progenitor cell population in developing hu...
Next Document:  Polyolefin backbone substitution in binders for low temperature powder injection moulding feedstocks...